{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:41:17Z","timestamp":1791600077422,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.esmoop.2025.104480","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:58:06Z","timestamp":1747051086000},"page":"104480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genomic profiling unlocks new treatment opportunities for ampullary carcinoma"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-2690","authenticated-orcid":false,"given":"C.","family":"Fabregat-Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Castet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8458-516X","authenticated-orcid":false,"given":"D.","family":"L\u00f3pez-Valbuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6898-5502","authenticated-orcid":false,"given":"E.","family":"Pando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.V.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5856-4082","authenticated-orcid":false,"given":"T.","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2025.104480_bib1","first-page":"71","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"issue":"34","key":"10.1016\/j.esmoop.2025.104480_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.14694\/EdBook_AM.2014.34.112","article-title":"Ampullary cancer: an overview","author":"Ahn","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104480_bib3","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.3390\/curroncol28050293","article-title":"Ampullary carcinoma: an overview of a rare entity and discussion of current and future therapeutic challenges","volume":"28","author":"Rizzo","year":"2021","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104480_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.23736\/S1121-421X.18.02543-6","article-title":"Demographics, tumor characteristics, treatment, and clinical outcomes of patients with ampullary cancer: a Surveillance, Epidemiology, and End Results (SEER) cohort study","volume":"65","author":"Ramai","year":"2019","journal-title":"Minerva Gastroenterol Dietol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.104480_bib5","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1200\/JCO.2023.41.16_suppl.4168","article-title":"Incidence, epidemiological characteristics, and cause-specific survival analysis of ampullary carcinoma using the SEER database","volume":"41","author":"Gor","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104480_bib6","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1245\/s10434-008-9886-1","article-title":"Survival after resection of ampullary carcinoma: a national population-based study","volume":"15","author":"O\u2019Connell","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104480_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.6004\/jnccn.2023.0034","article-title":"Ampullary adenocarcinoma, version 1.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Chiorean","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"10391","key":"10.1016\/j.esmoop.2025.104480_bib8","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104480_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104480_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"J Am Med Assoc"},{"issue":"14","key":"10.1016\/j.esmoop.2025.104480_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104480_bib12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104480_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2025.104480_bib14","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.3390\/cancers15245772","article-title":"Ampullary adenocarcinoma: a review of the mutational landscape and implications for treatment","volume":"15","author":"Tsagkalidis","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.esmoop.2025.104480_bib15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.celrep.2015.12.005","article-title":"Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation","volume":"14","author":"Gingras","year":"2016","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104480_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","article-title":"Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma","volume":"29","author":"Yachida","year":"2016","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104480_bib17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-019-0415-8","article-title":"Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study","volume":"120","author":"Perkins","year":"2019","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104480_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/modpathol.2013.185","article-title":"Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels","volume":"27","author":"Mikhitarian","year":"2014","journal-title":"Mod Pathol"},{"issue":"2D","key":"10.1016\/j.esmoop.2025.104480_bib19","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7051","article-title":"Molecular targets and therapies for ampullary cancer","volume":"22","author":"Patel","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104480_bib20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","article-title":"Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients","volume":"185","author":"Nguyen","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2025.104480_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104480_bib22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/PAS.0000000000000230","article-title":"The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater","volume":"38","author":"Ang","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104480_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/1878-0261.12099","article-title":"Analysis of mutant allele fractions in driver genes in colorectal cancer \u2013 biological and clinical insights","volume":"11","author":"Dienstmann","year":"2017","journal-title":"Mol Oncol"},{"key":"10.1016\/j.esmoop.2025.104480_bib24","doi-asserted-by":"crossref","first-page":"V810","DOI":"10.1093\/annonc\/mdz269.044","article-title":"VHIO-300 and a thousand and one nights: a tale of precision medicine","volume":"30","author":"Carat\u00f9","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104480_bib25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104480_bib26","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.3390\/curroncol30070507","article-title":"Ampullary cancer: histological subtypes, markers, and clinical behaviour-state of the art and perspectives","volume":"30","author":"Nappo","year":"2023","journal-title":"Curr Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104480_bib27","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s00423-022-02563-z","article-title":"The impact of the histological classification of ampullary carcinomas on long-term outcomes after pancreaticoduodenectomy: a single tertiary referral center evaluation","volume":"407","author":"Quero","year":"2022","journal-title":"Langenbecks Arch Surg"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104480_bib28","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104480_bib29","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.esmoop.2025.104480_bib30","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","article-title":"FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104480_bib31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104480_bib32","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/neuonc\/noac087","article-title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)","volume":"24","author":"Desai","year":"2022","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.104480_bib33","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104480_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104480_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"7691","key":"10.1016\/j.esmoop.2025.104480_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104480_bib37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104480_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00306","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study","volume":"6","author":"Gupta","year":"2022","journal-title":"JCO Precis Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925003497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925003497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:47:16Z","timestamp":1757576836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925003497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2059702925003497"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104480","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic profiling unlocks new treatment opportunities for ampullary carcinoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104480"}}